Drug Profile


Alternative Names: BY 2001; Lung surfactant factor; Recombinant surfactant protein C; rSP-C; Venticute

Latest Information Update: 02 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scios
  • Developer Nycomed
  • Class Phospholipids; Pulmonary surfactants; Recombinant proteins; Surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult respiratory distress syndrome

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome

Most Recent Events

  • 01 Jun 2007 Lusupultide received Fast Track designation for Adult respiratory distress syndrome [Intratracheal] in the US
  • 02 Sep 2004 A study has been added to the Respiratory Tract Disorders therapeutic trials section
  • 16 Jun 2004 Phase-III clinical trials in Adult respiratory distress syndrome in European Union (Intratracheal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top